Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

348
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
348
Real Time RT-PCR02:57

Real Time RT-PCR

63.9K
Real-time reverse transcription-polymerase chain reaction, or Real-time RT-PCR, is an analytical tool used to determine the expression level of target genes. The method involves converting mRNA to complementary DNA with the help of an enzyme known as reverse transcriptase, followed by the PCR amplification of the cDNA. These two processes can be performed simultaneously in a single tube or separately as a two-step reaction.
The real-time quantification of the number of amplified products is...
63.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navigating The Prostate Cancer Frontier: A Bibliometric and Altmetric Analysis of [<sup>225</sup>Ac]Ac-PSMA Therapy.

Seminars in nuclear medicine·2024
Same author

Clinical perspectives on dosimetry in molecular radiotherapy.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2023
Same author

Clinical Utility of <sup>18</sup>Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (<sup>18</sup>F-FDG PET/CT) in Multivisceral Transplant Patients.

Journal of imaging·2023
Same author

Radiological and Clinical Efficacy of Intra-Arterial <sup>90</sup>Y-DOTATATE in Patients with Unresectable, Progressive, Liver Dominant Neuroendocrine Neoplasms.

Journal of clinical medicine·2021
Same author

ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223.

American journal of clinical oncology·2020
Same author

COVID-19: guidance for infection prevention and control in nuclear medicine.

Nuclear medicine communications·2020

Related Experiment Video

Updated: Dec 12, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.7K

Evidence Base for the Use of PRRT.

John R Buscombe1

  • 1Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa.

Seminars in Nuclear Medicine
|August 10, 2020
PubMed
Summary

Peptide receptor radionuclide therapy (PRRT) offers significant survival and symptom relief benefits for neuroendocrine tumors (NETs). A randomized trial confirmed PRRT as a safe, effective treatment choice for hormone-refractory NETs.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Pharmacology

Background:

  • Peptide receptor radionuclide therapy (PRRT) development for neuroendocrine tumors (NETs) faced challenges in clinical translation and regulatory processes.
  • Early studies lacked rigorous data, despite growing evidence of PRRT's efficacy in improving survival and symptom relief for approximately 80% of patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of PRRT compared to standard treatment in patients with neuroendocrine tumors.
  • To establish PRRT as a definitive treatment option for hormone-refractory NETs.

Main Methods:

  • A decade and a half of research culminated in a formal randomized controlled trial.
  • The trial compared PRRT directly against high-dose somatostatin therapy.

More Related Videos

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP
06:36

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Published on: April 9, 2013

22.0K
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.5K

Related Experiment Videos

Last Updated: Dec 12, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.7K
PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP
06:36

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Published on: April 9, 2013

22.0K
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.5K

Main Results:

  • PRRT demonstrated a positive benefit in survival and symptom relief in a significant majority of patients.
  • The randomized trial conclusively proved PRRT's safety and effectiveness.

Conclusions:

  • PRRT is a safe and effective treatment for neuroendocrine tumors.
  • PRRT is the treatment of choice for hormone-refractory NETs, offering improved outcomes.